ClinicalTrials.gg
CompletedNCT02172586Updated Jun 24, 2014

Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients

A Phase 4 interventional study of Telmisartan and Losartan in Hypertension, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-24.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
363
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
37th of 99
363 · median 184
Started
2000
with 5 others
Phase 4
32 of 99
1 open now
Registered
55th of 99
by date
Lead sponsor
48 of 99
Boehringer Ingelheim

Among the 99 studies testing telmisartan in Hypertension, this one is the 37th largest by enrollment, is one of 6 that started in 2000, is one of 32 in phase 4, and was the 55th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

Study to assess the efficacy of telmisartan 40-80 mg once daily compared with losartan 50-100 mg once daily in hypertensive patients evaluated by change from baseline in diastolic blood pressure (DBP) during the last 6 hours of the 24-hour dosing interval, at the end of the 12 weeks period of monotherapy treatment (ABPM - ambulatory blood pressure measurement).

Secondary objectives: Changes from baseline in BP at the end of the monotherapy period of treatment and at the end of the study, evaluated by sphygmomanometric blood pressure measurement and ABPM

Safety:

Incidence of adverse events (AE's); withdrawal due to adverse events; laboratory parameters

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Mild-to-moderate essential hypertension defined as a mean diastolic blood pressure (DBP) ≥ 95 mmHg and \< 110 mmHg and systolic blood pressure (SBP) \< 180 mmHg measured by manual cuff sphygmomanometer at the end of the
  • Written

Exclusion criteria

Exclusion Criteria:

  • Nursing, pregnancy or women, women will be enrolled with last menstruation > 1 year prior to start wash-out phase or surgically sterile
  • Secondary hypertension
  • Malignant hypertension (retinal haemorrhage, exudates or papillary oedema)
  • sodium depletion as defined by serum sodium level \< 130 mEq/L and/or clinically significant hyperkaliemia as defined by serum potassium level > 5.5 mEq/L or clinically significant hypokaliemia as defined by serum potassium level \< 3.0 mEq/L
  • Atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which, in the investigator opinion could compromise patient's participation to the trial
  • Congestive heart failure (CHF) ( (New York Heart Association) functional class CHF III-IV)
  • Angina pectoris or myocardial infarction
  • Cardiac surgery within the past 3 months prior to start the
  • Stroke within the past 6 months prior to start the wash-out period
  • Renal insufficiency defined as creatininaemia > 2mg/dl
  • Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post renal transplant, presence of only one functioning kidney
  • Liver insufficiency, defined as bilirubinaemia > 2mg/dl and (aspartate aminotransferase) or ALT (alanine-aminotransferase) > twice the upper normal range
  • Clinically significant metabolic and endocrine disease
  • disease
  • Previous history of angioedema
  • > 30kg/m2
  • Arm circumference > 32 cm
  • Any condition that may be likely to compromise patients participation to the trial (alcohol or drug abuse, disability illness, etc.)
  • Concomitant therapy with antihypertensive drugs non permitted by protocol, or drugs known to affect blood pressure
  • Concomitant use of lithium or cholestyramine or colestipol resins (potential drug interactions with HCTZ)
  • drug treatment within the past 30 days before the enrolment or concurrent participation to any other trial
  • Sensitivity, significant adverse reaction or to the study drugs (telmisartan, losartan, HCTZ)
  • Predictable lack of patient co-operation
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
363 participants (actual)

Study arms

  • Experimental
    Telmisartan

    Drug: Telmisartan

  • Experimental
    Telmisartan + Hydrochlorothiazide

    Drug: Telmisartan · Drug: Hydrochlorothiazide

  • Active comparator
    Losartan

    Drug: Losartan

  • Active comparator
    Losartan + Hydrochlorothiazide

    Drug: Losartan · Drug: Hydrochlorothiazide

06

What researchers measure

Primary outcomes

  1. Change from baseline in diastolic blood pressure (DBP) during the last 6 hours (ABPM - ambulatory blood pressure measurement) of the 24-hour dosing interval at the end of the monotherapy period of treatment

    Time frame: Baseline and week 12

Secondary outcomes

  1. Change from baseline in DBP during the last 6 hours (ABPM) of the 24-hour dosing interval at the end of the study

    Time frame: Baseline and week 24

  2. Change from baseline in systolic blood pressure (SBP) during the last 6 hours (ABPM) of the 24-hour dosing interval

    Time frame: Baseline, week 12 and 24

  3. Change from baseline in DBP/SBP during the last 2 hours (ABPM) of the 24-hour dosing interval (trough BP)

    Time frame: Baseline, week 12 and 24

  4. Changes from baseline in trough cuff (sphygmomanometer) SBP/DBP

    Time frame: Baseline, week 12 and 24

  5. Changes from baseline in SBP/DBP of 24 hours mean ABPM

    Time frame: Baseline, week 12 and 24

  6. Comparison of SBP/DBP ABPM tracing profile

    Time frame: Week 12 and 24

  7. Smoothness index in comparison with baseline

    Time frame: Baseline, week 12 and 24

  8. Number of responders

    Time frame: Week 12 and 24

  9. Number of controlled responders

    Time frame: Week 12 and 24

  10. Number of patients who withdraw due to lack of efficacy

    Time frame: 24 weeks

  11. Number of patients with adverse events

    Time frame: 24 weeks

  12. Number of patients who withdraw due to adverse events

    Time frame: 24 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2000 and a primary completion of Jan 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 24, 2014
Start
Jan 2000
Primary completionActual
Jan 2002
Last update
Jun 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02172586
Responsible party
Sponsor
First posted
Jun 24, 2014
Start date
Jan 2000
Primary completion
Jan 2002
Last update
Jun 24, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Hydrochlorothiazide

Start the discussion